GENENTECH IS GRANTED PATENTS FOR RECOMBINANT FACTOR VIII.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--April 9, 1997-- Genentech, Inc. (NYSE NYSE See: New York Stock Exchange : GNE GNE Gateway Network Element (data communications) GNE Game Neverending (MMORPG) GNE Gross National Expenditure GNE Game Networking Engine GNE Graphical Network Editor (Nortel) ) today announced that the U.S. Patent Office has granted Genentech U.S. Patents numbered 5,618,788 and 5,618,789 for methods of treating hemophiliacs with recombinant human Factor VIII factor VIII n. A factor in the clotting of blood, a deficiency of which is associated with hemophilia A. Also called antihemophilic factor, antihemophilic globulin, antihemophilic globulin A, and recombinant human Factor VIII as a pharmaceutical product, respectively. A corresponding European patent was granted in 1991 and was unopposed. Genentech continues to receive royalties on the recombinant human Factor VIII product. "We are very pleased by the issuance of these important patents to Genentech and especially by the contribution that our work in making available recombinant human Factor VIII has had to the lives of patients with hemophilia," said Janet Hasak, Genentech's manager of Patent Prosecution and Trademarks. The patents are based upon applications filed with the U.S. Patent and Trademark Office in April 1984. The new patent 5,618,788 was involved in a three-way interference with U.S. patent applications assigned to Chiron Corporation and Genetics Institute, Inc. The U.S. Board of Patent Appeals and Interferences The Board of Patent Appeals and Interferences (BPAI) is a body of the United States Patent and Trademark Office (USPTO), which decides issues of patentability. If an applicant for an invention cannot convince a patent examiner that they are entitled to their claims, then the determined Genentech inventors were first to invent the subject matter claimed in the interference. The new patents are within the scope of the license agreement Genentech entered into in late 1984 with Miles Laboratories, Inc., Cutter Group, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Bayer AG. The agreement gave Miles an exclusive right to manufacture, use and sell recombinant human Factor VIII worldwide. Subsequently, Miles sublicensed non-exclusively part of its rights through agreements with Baxter Healthcare Corporation and Genetics Institute. Rhone-Poulenc Rorer, Inc. was granted distribution rights. Genentech and is leading biotechnology company that discovers, develops, manufactures, and markets human pharmaceuticals for significant unmet medical needs. Eleven of the currently marketed biotechnology products stem from Genentech science, six of which Genentech markets directly in the United States. The company has headquarters in South San Francisco, Calif. and is traded on the New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of and Pacific Stock Exchanges under the symbol GNE. CONTACT: Genentech, Inc. Laura Leber, 415/225-5759 (Media) Susan Bentley, 415/225-1034 (Investors) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion